Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4294069 | 0.97 | HRH3 (0.43) | USP2KMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL13660620 | 0.86 | ALDH1A1 (0.48) | KMT2AMEN1ALOX15ALDH1A1MAPT | |
| SCHEMBL13660613 | 0.83 | ALDH1A1 (0.56) | KMT2AMEN1ALOX15ALDH1A1NPSR1 | |
| SCHEMBL7177824 | 0.80 | HRH3 (0.46) | HRH3ALDH1A1 | |
| SCHEMBL7177818 | 0.80 | HRH3 (0.46) | HRH3ALDH1A1 | |
| SCHEMBL4299069 | 0.75 | TGM2 (0.52) | HRH3LMNA | |
| SCHEMBL4299067 | 0.75 | TGM2 (0.52) | HRH3LMNA | |
| SCHEMBL4293467 | 0.73 | HRH3 (0.49) | CYP3A4HRH3 | |
| SCHEMBL4293472 | 0.73 | HRH3 (0.49) | CYP3A4HRH3 | |
| SCHEMBL4296886 | 0.73 | HRH3 (0.58) | KMT2ATDP1HRH3ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | APODACA RICHARD | 2009-10-22 | — | — | US | disclosed |
| US-20050288323-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | APODACA RICHARD | 2005-12-29 | — | — | US | disclosed |
| US-20040167336-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | APODACA RICHARD (US) | 2004-08-26 | — | — | US | disclosed |
| US-20030013733-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288323-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | HRH4, HNMT, HRH1 | USP2 2064/4885KMT2A 1283/4885MEN1 2270/4885 |
| US-20030013733-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | HRH4, HNMT, HRH1 | USP2 2064/4885KMT2A 1283/4885MEN1 2270/4885 |
| US-20040167336-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | HRH4, HNMT, HRH1 | USP2 2064/4885KMT2A 1283/4885MEN1 2270/4885 |
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | HRH4, HNMT, HRH1 | USP2 2032/4885KMT2A 1231/4885MEN1 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.